HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Chemotherapeutics in Metastatic Breast Cancer

January 22nd 2014

CDK4/6 Inhibitors in Metastatic Breast Cancer

January 22nd 2014

Next Steps for Everolimus in Metastatic Breast Cancer

January 22nd 2014

Upfront Treatment of HR-Positive MBC

January 22nd 2014

Case Study: HER2-Positive Oligometastatic Breast Cancer

January 22nd 2014

Phase III Clinical Trials in HER2-Positive Breast Cancer

January 22nd 2014

Novel Drug Development in Breast Cancer

January 22nd 2014

Role of Lapatinib in HER2-Positive Breast Cancer

January 22nd 2014

Recommendations for Optimal HER2 Testing in Breast Cancer

January 22nd 2014

T-DM1 in HER2-Positive Metastatic Breast Cancer

January 22nd 2014

PIK3CA Mutations in HER2-Positive Breast Cancer

January 22nd 2014

Frontline Pertuzumab for Metastatic Breast Cancer

January 22nd 2014

Treating Low-Risk HER2-Positive Breast Cancer

January 22nd 2014

Overview of HER2-Targeted Therapies in Breast Cancer

January 22nd 2014

Gradishar Provides Insight into New Breast Cancer Treatments

January 21st 2014

New treatments for HER2-positive (HER2+) tumors have dominated media coverage of breast cancer breakthroughs over the past year, but William Gradishar sees promise on many fronts.

BOLERO-3 Safety Analysis Finds Everolimus Regimen Is Manageable

December 13th 2013

The combination of everolimus, trastuzumab, and vinorelbine, as given in the BOLERO-3 trial in patients with pretreated HER2-positive advanced breast cancer, is adequately tolerated, and adverse events are manageable.

NeoALTTO Analysis Finds Significant Link Between pCR and Survival

December 12th 2013

Pathologic complete response to neoadjuvant chemotherapy had a significant correlation with survival in early HER2-positive breast cancer after 4 years of follow-up.

No Benefit Found in Adding Bevacizumab to Adjuvant Therapy in HER2-Positive Breast Cancer

December 12th 2013

Bevacizumab did not improve invasive disease-free survival or overall survival when added to adjuvant therapy for HER2-positive breast cancer in the large randomized BETH trial.

High Levels of Infiltrating Lymphocytes May Identify Better Response to Trastuzumab

December 12th 2013

New evidence suggests that HER2-positive breast cancer may not only be immunogenic, but also that trastuzumab may relieve suppression of antitumor immunity.

Dr. Loi on the Association Between TILs and Trastuzumab

December 11th 2013

Sherene Loi, MD, PhD, on the association between immune cells and a pathologic complete response in patients with breast cancer after being given chemotherapy and trastuzumab.